Table 1.
Baseline Clinical Characteristics of the Population Divided According to LVEF Categories
| Total 812 pts | rEF DCM 637 pts | mrEF DCM 175 pts | P Value | |
|---|---|---|---|---|
| Age, y | 46 (36;56) | 48 (37;57) | 42 (32;50) | 0.001 |
| Male sex (%) | 565 (70%) | 455 (71%) | 110 (63%) | 0.029 |
| NYHA III–IV, n (%) | 195 (24) | 186 (29) | 9 (5) | <0.001 |
| SBP, mm Hg | 124±18 | 123±18 | 126±17 | 0.27 |
| Heart rate, bpm | 78±16 | 80±16 | 70±12 | <0.001 |
| LBBB (%) | 256 (32%) | 221 (35%) | 35 (20%) | <0.001 |
| Echocardiography | ||||
| LAESAI, cm2/m2 | 14±4 | 14±4 | 11±3 | <0.001 |
| LVEDDI, mm/m2 | 36±6 | 37±6 | 32±4 | <0.001 |
| LVEDVI, mL/m2 | 99±37 | 106±37 | 71±18 | <0.001 |
| LVEF, % | 31±10 | 27±7 | 44±3 | <0.001 |
| RVD, n (%) | 199 (26) | 182 (30) | 17 (10) | <0.001 |
| Moderate–severe MR, n (%) | 285 (36) | 262 (42) | 23 (13) | <0.001 |
| Restrictive LV filling pattern, n (%) | 233 (30) | 225 (37) | 8 (5) | <0.001 |
| E/E′ | 14±7 | 15±8 | 10±3 | <0.001 |
| sPAP | 35±14 | 37±15 | 25±5 | <0.001 |
| Therapy | ||||
| ACE‐inhibitors‐ARBs, n (%) | 783 (96) | 624 (98) | 159 (91) | 0.081 |
| Beta‐blockers, n (%) | 729 (90) | 576 (91) | 153 (88) | 0.311 |
| Diuretics, n (%) | 607 (75) | 531 (84) | 76 (44) | <0.001 |
| MRAs, n (%) | 239 (30) | 216 (34) | 23 (13) | <0.001 |
Values are expressed as mean±SD or median with interquartile range as appropriate, and as percentage. ACE indicates angiotensin‐converting enzyme; ARBs, angiotensin receptor blockers; LAESAI, left atrial end systolic area indexed; LBBB, left bundle branch block; LV, left ventricular; LVEDDI, left ventricular end‐diastolic diameter indexed; LVEDVI, left ventricular end‐diastolic volume indexed; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; MRAs, mineralocorticoid receptor antagonists; NYHA, New York Heart Association; RVD, right ventricular dysfunction; SBP, systolic blood pressure; sPAP, systolic pulmonary artery pressure.